Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae
Abstract
Although quinolones have been recommended for treatment of pneumonia due to Chlamydia pneumoniae (1), data on the use of these antibiotics for this indication are limited. Previously published treatment studies of quinolones for community-acquired pneumonia have used serology for the diagnosis ofC. pneumoniae infection; thus, microbiological efficacy could not be assessed (1, 4, 5). We obtained nasopharyngeal specimens for culture of C. pneumoniae from patients, 18 years of age or older, with community-acquired pneumonia who were enrolled in an open, noncomparative, multicenter study evaluating 500 mg of levofloxacin given intravenously or orally once a day for 7 to 14 days. Cultures were obtained at baseline and 5 to 7 days and 21 to 28 days after treatment. Susceptibility testing of C. pneumoniae was performed in cell culture using HEp-2 cells as previously described (6). Cultures for C. pneumoniae were obtained from 646 patients; 47 (7.3%) were positive at one or more study visits. C. pneumoniae was eradicated from the nasopharynx in 16 (80%) of the 20 evaluable culture-positive patients after treatment. In vitro susceptibility testing for levofloxacin was performed on eight isolates of C. pneumoniae from these patients. The MICs and minimal bactericidal concentrations (MBCs) for these isolates ranged from 0.125 to 0.5 μg/ml and were the same at baseline and after therapy (Table1).Table 1.In vitro susceptibilities to levofloxacin of C. pneumoniae isolates from four…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.